Shares are trading at $2.13 which is quite a bit lower than $2.59, the 50 day moving average and impressively higher than the 200 day moving average of $1.88. The 50 day moving average went down $-0.46 or -17.67% whereas the 200 day average was up by +13.51%. Trading volume for Applied DNA Sciences Inc was 169K in the last trading session. Shares saw a steep increase in trading volume of 49.29% over the normal average daily volume.
Traders are more bullish on Applied DNA Sciences Inc of late at least if you consider the change in short interest. The company had a fall in short interest between September 29, 2017 and October 13, 2017 of -6.52%. Short interest decreased 49,392 over that timeframe. Days to cover decreased from 12.0 to 5.0 and the percentage of shorted shares was 0.03% on October 13.
A few notable investment firms have updated their holdings. Citadel Advisors LLC added to its ownership by buying 515 shares an increase of 4.9% in the quarter. Citadel Advisors LLC now controls 11,100 shares valued at $20,000. The total value of its holdings decreased 44.4%. As of quarter end Sabby Management, LLC had sold 784,246 shares trimming its stake by 44.3%. The value of the investment in (APDN) went from $2,930,000 to $1,738,000 decreasing 40.7% quarter over quarter.
As of the end of the quarter Creative Planning had acquired a total of 200 shares growing its holdings by 0.3%. The value of the investment in Applied DNA Sciences Inc increased from $135,000 to $221,000 a change of 63.7% since the last quarter. As of quarter end Cable Hill Partners, LLC had bought 1,000 shares growing its position 12.5%. The value of the company’s investment in Applied DNA Sciences Inc increased from $14,000 to $26,000 a change of $12,000 quarter to quarter.
In the last earnings report the EPS was $-0.49 and is projected to be $-0.44 for the current year with 27,377,000 shares presently outstanding. Analysts expect next quarter’s EPS will be $-0.10 and the next full year EPS is anticipated to be $-0.23.
Applied DNA Sciences, Inc., launched on December 17, 2008, is involved in creating security solutions addressing the challenges of modern commerce. The Company is also engaged in the large-scale production of specific deoxyribonucleic acid (DNA) sequences using the polymerase chain reaction (PCR). The Business’s principal technology platform includes SigNature DNA, SigNature T DNA, fiberTyping, DNAnet, digitalDNA, SigNify and Beacon. The Business’s SigNify IF portable DNA reader provides definitive real-time authentication of SigNature DNA in the field-DNA becomes a solution for supply chain integrity..